Showing results (801-810 of 1,193) with videos related to
Sort By:
Pageof 120
Pharmaceutical Statistics|June 3, 2017
Adaptive power priors with empirical Bayes for clinical trialsIsaac Gravestock, Leonhard Held, Pharmaceutical Statistics|November 12, 2009
The impact of dichotomization in longitudinal data analysis: a simulation studyBongin YooPharmaceutical Statistics|April 19, 2018
How to use prior knowledge and still give new data a chance?Kristina Weber, Rob Hemmings, Armin KochPharmaceutical Statistics|September 27, 2012
A bivariate Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritisHelene Thygesen, Vladimir Dragalin, Anne Whitehead, et al.Pharmaceutical Statistics|January 23, 2015
Adaptive and repeated cumulative meta-analyses of safety data during a new drug development processHui Quan, Yingqiu Ma, Yan Zheng, et al.Pharmaceutical Statistics|October 13, 2012
The challenges of evaluating dose response in flexible-dose trials using marginal structural modelsIlya Lipkovich, Craig H Mallinckrodt, Douglas E FariesPharmaceutical Statistics|September 22, 2012
Joint modeling of hierarchically clustered and overdispersed non-gaussian continuous outcomes for comet assay dataAklilu Habteab Ghebretinsae, Christel Faes, Geert Molenberghs, et al.Pharmaceutical Statistics|July 19, 2022
Evaluating response-adaptive randomization procedures for recurrent events and terminal event data using a composite endpointYu-Lin Mau, Pei-Fang SuPharmaceutical Statistics|May 22, 2023
How to avoid concerns with the interpretation of two primary endpoints if significant superiority in one is sufficient for formal proof of efficacyAnika Großhennig, Nele Henrike Thomas, Werner Brannath, et al.Pharmaceutical Statistics|March 3, 2023
Utilization of treatment effect on a surrogate endpoint for planning a study to evaluate treatment effect on a final endpointHui Quan, Zhixing Xu, Junxiang Luo, et al.Pageof 120